The Molecular Basis of Inherited Reproductive Disorders
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Study Coordinator
- Phone Number: 617-643-2308
- Email: reproendogenetics@partners.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Participants must be healthy controls or belong to one of the following categories:
- Failure to go through a normal, age-appropriate, spontaneous puberty and low sex steroid levels in the setting of low/normal gonadotropins or,
- Abnormally early development of puberty or,
- Normal puberty with subsequent development of low gonadotropin levels or,
- Evidence of a reproductive disorder with high gonadotropin levels or,
- Pre-pubertal individuals with features suggestive of hypogonadotropic hypogonadism or,
- Affected and unaffected family members of individuals that fit criteria above
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Subjects with Reproductive Disorders or Healthy controls
Healthy controls or individuals with reproductive disorders and their affected and unaffected family members
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Genetic variation
Time Frame: Day 1
|
Identification of one or more genetic variations related to reproductive disorders
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stephanie Seminara, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Endocrine System Diseases
- Male Urogenital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genetic Diseases, Inborn
- Gonadal Disorders
- Congenital Abnormalities
- Disorders of Sex Development
- Urogenital Abnormalities
- Disorder of Sex Development, 46,XY
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Hypogonadism
- Puberty, Delayed
- Kallmann Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 2020P000762
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.